The central theme of the Cancer Prevention and Control (CPC) program is to translate its research findings into practice and policy to improve the prevention, detection, treatment, and control of cancer. The CPC program strives to enhance the quality of life of all individuals affected by cancer, including a large African American population served within the MCC catchment area. MCC received distinction as a Minority Based NCI Oncology Research Program Community Site to further advance research in this important area of need. Additionally, CPC clinical trials and much of the program?s basic science research addresses disparities in this population. The CPC program has 36 members representing 12 departments and 4 schools. Currently, the CPC program has a total peer-reviewed cancer-related funding base of approximately $6.5 million in direct costs, of which nearly $2.3 million is from the NCI and over $3 million is from other NIH institutes. During 2011 to 2015, the CPC program had a total of 475 publications, of which 22% were intraprogrammatic and 10% were interprogrammatic. The scientific goals of the program are highlighted by its themes of (1) reducing cancer risk and (2) improving cancer-related care, both of which are tied together by the cross-cutting theme of alleviating disparities. CPC continues to achieve significant impact in these areas as evidenced by the program?s accomplishments of: translating MCC basic science findings into clinical trials for a novel smoking cessation therapy (now in phase IIa clinical trials in collaboration with the University of Pittsburgh Cancer Institute); informing the FDA and WHO tobacco policy on modified-risk tobacco products such as e-cigarettes with CPC?s first multi-PI P50 grant; decreasing cancer risk through obesity control in high-risk populations? adolescents and African Americans; improving cancer screening decision making; enhancing patient and caregiver experience with cancer care; identifying Medicaid and other policy effects on access to care; identifying barriers to African American enrollment in clinical research trials; and developing methods to overcome these barriers. In line with the NCI priority to foster multidisciplinary research, MCC has facilitated cross-cutting collaborations by generating an award program dedicated to CPC interprogrammatic pilot projects, several of which have recently led to large externally-funded grant projects. Value is added by MCC shared resources and CPC-sponsored education and training through monthly seminars, interprogrammatic research retreats, competitive CPC pilot grants, and through support of student and trainee fellowships. In summary, the CPC program is a vital, dynamic, and growing program within MCC, which addresses the unique needs of the MCC catchment area, as well as the nation more generally. The program, with its vibrant research agenda, engaged multidisciplinary membership, and ongoing support from MCC is well poised to continue to build upon the impact of its high-quality basic science, clinical, policy, and outcomes research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-37S3
Application #
9758994
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
37
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yamada, Akimitsu; Nagahashi, Masayuki; Aoyagi, Tomoyoshi et al. (2018) ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res 16:1059-1070
Cantwell, Marc T; Farrar, Jared S; Lownik, Joseph C et al. (2018) STAT3 suppresses Wnt/?-catenin signaling during the induction phase of primary Myf5+ brown adipogenesis. Cytokine 111:434-444
Aqbi, Hussein F; Wallace, Matthew; Sappal, Samay et al. (2018) IFN-? orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol :
Volker, Sonja E; Hedrick, Shannon E; Feeney, Yvonne B et al. (2018) Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78:3877-3887
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719
Damle, S R; Martin, R K; Cockburn, C L et al. (2018) ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production. Allergy 73:125-136
Wang, Feng; Li, Hongyan; Markovsky, Ela et al. (2018) Pazopanib radio-sensitization of human sarcoma tumors. Oncotarget 9:9311-9324
Stokes, Nancy A; Stanciu, Cristina E; Brocato, Emily R et al. (2018) Simplification of complex DNA profiles using front end cell separation and probabilistic modeling. Forensic Sci Int Genet 36:205-212
Poklepovic, Andrew; Qu, Yuesheng; Dickinson, Molly et al. (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 4:

Showing the most recent 10 out of 586 publications